OrbiMed Israel GP Ltd.

This profile gathers the share dealings of OrbiMed Israel GP Ltd. across 3 companies, led by 9 Meters Biopharma, Inc., Chemomab Therapeutics Ltd. and Eledon Pharmaceuticals, Inc. We count 14 filings; the first trade dates from 9 May 2017 and the latest from 3 January 2023.

On the open market, the record shows 1 purchase worth €1.8M and 6 sales worth €20.5M. Netting one side against the other leaves €18.7M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 5 share grants. So far in 2023, the count stands at no purchases and 2 sales.

The newest entry dates from 5 January 2023: an open-market sale of €298k, in Chemomab Therapeutics Ltd. The most recent open-market purchase was published on 6 May 2019, 2,727 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.